Matinas BioPharma Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

GOING CONCERN AND PLAN OF OPERATION (Details Textual) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Going Concern And Plan Of Operation [Line Items]
Deficit accumulated during development stage	$ 8,395,613		$ 8,395,613		$ 3,830,719
Net loss	$ 2,425,872	$ 343,314	$ 4,564,895	$ 455,447

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.